SARS-CoV-2 Spike Protein and Renal Cell Carcinoma
Author Information
Author(s): Maryna Somova, Stefan Simm, Jens Ehrhardt, Janosch Schoon, Martin Burchardt, Pedro Caetano Pinto
Primary Institution: University Medicine Greifswald
Hypothesis
Does the SARS-CoV-2 spike protein amplify the immunogenicity of healthy renal epithelium in the presence of renal cell carcinoma?
Conclusion
The study suggests that the presence of renal cell carcinoma amplifies the immune-modulatory effects of the SARS-CoV-2 spike protein on renal epithelial cells, potentially increasing the risk of complications for RCC patients during COVID-19.
Supporting Evidence
- The SARS-CoV-2 spike protein was internalized by renal proximal tubule epithelial cells but poorly interacted with renal cell carcinoma cells.
- Exposure to the spike protein led to increased expression of genes involved in immune responses in renal epithelial cells.
- Co-culture with renal cell carcinoma cells amplified the secretion of pro-inflammatory cytokines like TNF-α.
Takeaway
This study shows that kidney cancer cells can make the immune response to the COVID-19 virus stronger, which might make kidney cancer patients sicker if they get COVID-19.
Methodology
The study used a microphysiological system to co-culture renal cell carcinoma cells with renal proximal tubule epithelial cells and exposed them to the SARS-CoV-2 spike protein to evaluate metabolic activity, gene expression, immune secretions, and protein internalization.
Limitations
The study did not incorporate immune cells into the microphysiological model, which may limit the understanding of the immune response.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website